Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other neoplasm 1Dermatologic 1

Conditions

Keratosis, Actinic 5Skin Diseases 1Precancerous Conditions 1Keratosis 1Carcinoma, Basal Cell 1

Interventions

binimetinib 2Watchful Waiting 2Aminolevulinic Acid 2palbociclib 1ipatasertib 1exemestane 1encorafenib 1baricitinib 1atezolizumab 1Vemurafenib 1VP-102 1Trabectedin 1Paclitaxel 1Injections, Intradermal 1Gonadotropin-Releasing Hormone 1Everolimus 1Dacarbazine 1Cantharidin 1BF-200 ALA 1Anastrozole 1AZD9833 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Skin Diseases × BF-200 ALA × Clear all
NCT05060237 2024-10-17

Study to Evaluate Safety and Tolerability of BF-200 ALA (Ameluz®) for Photodynamic Therapy in the Treatment of the Expanded Field of Actinic Keratosis on Face and Scalp

Biofrontera Bioscience GmbH

Phase 1 Completed
112 enrolled 21 charts
DermatologicOther neoplasm

Keratosis, Precancerous Conditions, Skin Diseases, Keratosis, Actinic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡